Buy IRESSA 250 mg/1 Gefitinib

IRESSA 250 mg tablets contain gefitinib, a medication used to treat certain types of cancer. This oral medication is designed for targeted therapy and is manufactured by AstraZeneca Pharmaceuticals LP.

Strength

250 mg/1

Pack Size

30 TABLET, COATED in 1 BOTTLE (0310-0482-30)

Manufacturer / TM Owner

AstraZeneca Pharmaceuticals LP

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Uses / Indications

IRESSA 250 mg tablets are primarily used in the treatment of specific types of non-small cell lung cancer. Gefitinib is a tyrosine kinase inhibitor that targets certain proteins involved in cancer cell growth. This medication is often prescribed for patients with specific genetic mutations that make their cancer cells dependent on these proteins for growth and survival. It is important to consult with a healthcare provider to determine if IRESSA 250 mg tablets are suitable for your condition.

Side Effects

Common effects of IRESSA 250 mg tablets may include skin rash, diarrhea, and nausea. Some users may also experience dry skin, loss of appetite, or changes in hair texture. These effects can vary in intensity and duration. If you experience severe or persistent side effects, it is advisable to seek medical attention.

Precautions & Warnings

IRESSA 250 mg tablets should be handled with care and stored as directed. It is important to follow the prescribed dosage and administration instructions provided by your healthcare provider. This medication may interact with other drugs, so it is crucial to inform your healthcare provider about all medications you are taking. Pregnant or breastfeeding women should consult their healthcare provider before using IRESSA 250 mg tablets.

Avoid Interactions

IRESSA 250 mg tablets may interact with certain medications, including those that are metabolized by the liver enzyme CYP3A4. This can affect the effectiveness of gefitinib or other drugs. It is important to avoid grapefruit and grapefruit juice, as they can also interact with gefitinib. Always inform your healthcare provider about all medications, supplements, and herbal products you are taking to minimize the risk of interactions.

References

Frequently Asked Questions

IRESSA 250 mg tablets are used to treat certain types of non-small cell lung cancer, particularly in patients with specific genetic mutations.

IRESSA 250 mg tablets are taken orally, usually once daily. Follow the instructions provided by your healthcare provider for the best results.

Common side effects may include skin rash, diarrhea, nausea, dry skin, loss of appetite, and changes in hair texture.

IRESSA 250 mg tablets may interact with other medications, so it is important to consult your healthcare provider before combining them with other drugs.

Pregnant or breastfeeding women should consult their healthcare provider before using IRESSA 250 mg tablets to ensure safety.

Published by GNH India Pharmaceuticals Limited

Last updated: 18 May 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.